Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368619 | 0.81 | GPR119 (0.43) | GPR119PGRCYP2D6CYP2C9MGLL | |
| SCHEMBL355381 | 0.80 | KDM1A (0.35) | GPR119PGRCYP2D6CYP2C9CETP | |
| SCHEMBL10140492 | 0.79 | GPR119 (0.41) | GPR119PGRCYP2D6CYP2C9MGLL | |
| SCHEMBL357663 | 0.76 | GPR119 (0.39) | GPR119PGRCYP2D6CYP2C9MGLL | |
| SCHEMBL357664 | 0.76 | GPR119 (0.39) | GPR119PGRCYP2D6CYP2C9MGLL | |
| SCHEMBL4540767 | 0.69 | GPR119 (0.41) | GPR119ACACBACACAMMP1MMP13 | |
| SCHEMBL12961781 | 0.67 | GPR119 (0.46) | GPR119MGLL | |
| SCHEMBL10139692 | 0.67 | GPR119 (0.35) | GPR119PGRCYP2D6CYP2C9MGLL | |
| SCHEMBL10171853 | 0.66 | KDM1A (0.36) | GPR119MGLL | |
| SCHEMBL1059433 | 0.66 | GPR119 (0.44) | GPR119ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | GPR119 1/4885PGR 339/4885CYP2D6 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.